questionsmedicales.fr
Maladies du système nerveux
Maladies du système nerveux central
Encéphalopathies
Épilepsie
Syndromes épileptiques
Épilepsies myocloniques
Épilepsies myocloniques progressives
Épilepsies myocloniques progressives : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques progressives : Questions médicales les plus fréquentes",
"headline": "Épilepsies myocloniques progressives : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Épilepsies myocloniques progressives : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-06",
"dateModified": "2025-03-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques progressives"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques",
"url": "https://questionsmedicales.fr/mesh/D004831",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques",
"code": {
"@type": "MedicalCode",
"code": "D004831",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques progressives",
"alternateName": "Myoclonic Epilepsies, Progressive",
"code": {
"@type": "MedicalCode",
"code": "D020191",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pasquale Striano",
"url": "https://questionsmedicales.fr/author/Pasquale%20Striano",
"affiliation": {
"@type": "Organization",
"name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Marte Syvertsen",
"url": "https://questionsmedicales.fr/author/Marte%20Syvertsen",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
},
{
"@type": "Person",
"name": "Deb K Pal",
"url": "https://questionsmedicales.fr/author/Deb%20K%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jeanette Koht",
"url": "https://questionsmedicales.fr/author/Jeanette%20Koht",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cisplatin Binding to Human Serum Transferrin: A Crystallographic Study.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36602395",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.inorgchem.2c04206"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies.",
"datePublished": "2023-05-12",
"url": "https://questionsmedicales.fr/article/37182407",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.semnephrol.2023.151341"
}
},
{
"@type": "ScholarlyArticle",
"name": "PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.",
"datePublished": "2023-02-23",
"url": "https://questionsmedicales.fr/article/36823640",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13018-023-03615-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35886942",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23147594"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy.",
"datePublished": "2023-03-16",
"url": "https://questionsmedicales.fr/article/36982788",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24065715"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002493"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphalopathies",
"item": "https://questionsmedicales.fr/mesh/D001927"
},
{
"@type": "ListItem",
"position": 5,
"name": "Épilepsie",
"item": "https://questionsmedicales.fr/mesh/D004827"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndromes épileptiques",
"item": "https://questionsmedicales.fr/mesh/D000073376"
},
{
"@type": "ListItem",
"position": 7,
"name": "Épilepsies myocloniques",
"item": "https://questionsmedicales.fr/mesh/D004831"
},
{
"@type": "ListItem",
"position": 8,
"name": "Épilepsies myocloniques progressives",
"item": "https://questionsmedicales.fr/mesh/D020191"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Épilepsies myocloniques progressives - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques progressives",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Épilepsies myocloniques progressives",
"description": "Comment diagnostiquer une épilepsie myoclonique progressive ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'EEG est-il essentiel pour le diagnostic ?\nPeut-on diagnostiquer cette épilepsie à tout âge ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Épilepsies myocloniques progressives",
"description": "Quels sont les principaux symptômes des épilepsies myocloniques progressives ?\nLes myoclonies sont-elles toujours présentes ?\nY a-t-il des troubles cognitifs associés ?\nLes crises peuvent-elles varier en intensité ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Épilepsies myocloniques progressives",
"description": "Peut-on prévenir les épilepsies myocloniques progressives ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes traumatismes crâniens peuvent-ils déclencher des crises ?\nLe stress peut-il aggraver les symptômes ?\nY a-t-il des recommandations pour les patients ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Épilepsies myocloniques progressives",
"description": "Quels traitements sont disponibles pour cette épilepsie ?\nLes médicaments sont-ils toujours efficaces ?\nY a-t-il des options chirurgicales ?\nLes thérapies complémentaires sont-elles utiles ?\nComment évaluer l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Épilepsies myocloniques progressives",
"description": "Quelles complications peuvent survenir ?\nLes patients sont-ils à risque de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nY a-t-il un risque accru de mortalité ?\nLes troubles du sommeil sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Épilepsies myocloniques progressives",
"description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie ?\nLes infections cérébrales sont-elles un facteur de risque ?\nLes troubles métaboliques peuvent-ils jouer un rôle ?\nLe sexe influence-t-il le risque d'épilepsie ?",
"url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Cisplatin&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une épilepsie myoclonique progressive ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, l'EEG et l'imagerie cérébrale."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques, un EEG et des examens d'imagerie sont souvent nécessaires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une épilepsie myoclonique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des secousses musculaires involontaires et des troubles cognitifs peuvent indiquer cette épilepsie."
}
},
{
"@type": "Question",
"name": "L'EEG est-il essentiel pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'EEG montre des anomalies typiques des crises myocloniques."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer cette épilepsie à tout âge ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien que les symptômes apparaissent souvent à l'adolescence ou au début de l'âge adulte."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes des épilepsies myocloniques progressives ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des myoclonies, des crises tonico-cloniques et une détérioration cognitive."
}
},
{
"@type": "Question",
"name": "Les myoclonies sont-elles toujours présentes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les myoclonies sont un symptôme caractéristique de cette condition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des troubles cognitifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une détérioration cognitive progressive est souvent observée."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles varier en intensité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la fréquence des crises peuvent varier d'un patient à l'autre."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la progression des symptômes est typique des épilepsies myocloniques progressives."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les épilepsies myocloniques progressives ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, mais un diagnostic précoce peut aider."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines formes d'épilepsies myocloniques progressives ont une composante génétique."
}
},
{
"@type": "Question",
"name": "Les traumatismes crâniens peuvent-ils déclencher des crises ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traumatismes crâniens peuvent augmenter le risque de crises chez les individus prédisposés."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver les symptômes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les crises et les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les patients ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients sont conseillés d'éviter les déclencheurs connus et de suivre leur traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette épilepsie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments antiépileptiques et parfois des thérapies complémentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils toujours efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments peuvent réduire les crises, mais leur efficacité varie selon les patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des options chirurgicales ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est rare mais peut être envisagée dans certains cas résistants au traitement."
}
},
{
"@type": "Question",
"name": "Les thérapies complémentaires sont-elles utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies comme la thérapie comportementale peuvent aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction de la fréquence et de l'intensité des crises."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des blessures dues aux crises et des troubles cognitifs sévères."
}
},
{
"@type": "Question",
"name": "Les patients sont-ils à risque de dépression ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent développer une dépression en raison de la maladie et de ses effets."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles entraîner des accidents ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de mortalité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de mortalité peut être plus élevé en raison de complications liées aux crises."
}
},
{
"@type": "Question",
"name": "Les troubles du sommeil sont-ils fréquents ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles du sommeil sont courants chez les patients atteints d'épilepsies myocloniques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux d'épilepsie et certains troubles neurologiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'épilepsie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge d'apparition est souvent entre 10 et 30 ans pour ces épilepsies."
}
},
{
"@type": "Question",
"name": "Les infections cérébrales sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent augmenter le risque de développer des épilepsies."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques peuvent-ils jouer un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles métaboliques sont associés à un risque accru d'épilepsie."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque d'épilepsie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines études montrent que le sexe peut influencer la prévalence des épilepsies."
}
}
]
}
]
}
The molecular mechanism of how human serum transferrin (hTF) recognizes cisplatin at the atomic level is still unclear. Here, we report the molecular structure of the adduct formed upon the reaction o...
Cisplatin is a highly effective chemotherapeutic agent that has been used for more than 50 years for a variety of cancers; however, its use is limited by toxicity, including nephrotoxicity. In this in...
Osteosarcoma is a common primary bone malignancy prevalent among adolescents and young adults. PTEN-induced kinase 1 (PINK1) regulates Parkinson's disease, but its role in cancers is unknown....
This study was designed to analyze the mechanism by which PINK1 affects osteosarcoma using bioinformatics and cell experiments....
The gene expression profiles were downloaded from the TARGET database. Several online databases were used to analyze the expression and protein‒protein interaction networks. CCK-8 cell viability assay...
Through bioinformatics analysis, we found that high expression of PINK1 was associated with poor prognosis in patients with osteosarcoma, and PINK1 inhibited apoptosis and promoted proliferation pathw...
Collectively, our findings demonstrate that PINK1 is crucially involved in osteosarcoma and suggests that it can promote the apoptosis of OS cells as the downstream target gene of cisplatin....
Platinum-based chemotherapy, cisplatin (DDP) specifically, is the main strategy for treating lung cancer (LC). However, currently, there is a lack of predictive drug-resistance markers, and there is i...
Data on miRNAs associated with LC DDP chemotherapy response are summarized and analyzed....
A comprehensive review of the data in the literature and an analysis of bioinformatics resources were performed. The gene targets of miRNAs, as well as their reciprocal relationships with miRNAs, were...
The complex analysis of bioinformatics resources and the literature indicated that the expressions of 12 miRNAs have a high predictive potential for LC DDP chemotherapy responses. The obtained informa...
An overview of the published data and bioinformatics resources, with respect to the predictive microRNA markers of chemotherapy response, is presented in this review. The selected microRNAs and gene p...
Natural compounds, such as resveratrol (Res), are currently used as adjuvants for anticancer therapies. To evaluate the effectiveness of Res for the treatment of ovarian cancer (OC), we screened the r...
Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demo...
We performed a mulitcenter, randomized phase III trial across 39 centers. Enrolled patients were randomly allocated (1:1) to either the GCS or GC arm. The GCS regimen comprised gemcitabine (1000 mg/m...
Between July 2014 and February 2016, 246 patients were enrolled. The median OS and 1-year OS rate were 13.5 months and 59.4% in the GCS arm and 12.6 months and 53.7% in the GC arm, respectively (hazar...
GCS is the first regimen which demonstrated survival benefits as well as higher RR over GC in a randomized phase III trial and could be the new first-line standard chemotherapy for advanced BTC. To ex...
Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The oto...
Cisplatin-based chemotherapy has been widely used in the treatment of lung adenocarcinoma (LUAD). However, the development of cisplatin resistance becomes a major obstacle impeding the curative effect...
Based on the CCLE database, lung cancer cell lines were divided into cisplatin-resistant and cisplatin-sensitive groups. The differentially expressed miRNAs were filtered and further identified by sur...
In this study, miR-375 showed the ability to promote cisplatin sensitivity and apoptosis of LUAD. Genes correlated with miR-375 in LUAD were analyzed and ABCC8 showed the strongest positive correlatio...
Overall, this study provides new insights into the role of miR-375 in the cisplatin sensitivity of LUAD. Our present findings may serve as a theoretical basis for new therapeutic strategies and predic...
With the scarcity of pharmacological otoprotective agents against cisplatin-induced ototoxicity (CIO), researchers find themselves compelled to look at and navigate all possible strategies to identify...
Osteosarcomas are prevalent in children and young adults and have a high recurrence rate. Cisplatin, doxorubicin, and methotrexate are common adjuvant chemotherapy drugs for treatment of osteosarcoma,...